Search
Search Results
-
Synergistic Combination Immunotherapy of Glioblastoma
Glioblastoma, a highly aggressive and malignant brain tumor classified as WHO grade IV, continues to pose a significant challenge despite the current...
-
-
Fractal-Based Morphometrics of Glioblastoma
Morphometrics have been able to distinguish important features of glioblastoma from magnetic resonance imaging (MRI). Using morphometrics computed on...
-
Multifractal Analysis of Brain Tumor Interface in Glioblastoma
The dynamics of tumor growth is a very complex process, generally accompanied by numerous chromosomal aberrations that determine its genetic and...
-
ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling
BackgroundCyclic nucleotides are critical mediators of cellular signalling in glioblastoma. However, the clinical relevance and mechanisms of...
-
Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes
Mounting evidence is identifying human cytomegalovirus (HCMV) as a potential oncogenic virus. HCMV has been detected in glioblastoma multiforme (GB)....
-
Overcoming multidrug resistance by reversan and exterminating glioblastoma and glioblastoma stem cells by delivering drug-loaded nanostructure hybrid lipid capsules (nHLCs)
Glioblastoma multiforme (GBM) is regarded as a highly aggressive brain cancer with a poor prognosis. There is an increase in the expression of...
-
VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis
BackgroundGlioblastoma is an aggressive brain tumor linked to significant angiogenesis and poor prognosis. Anti-angiogenic therapies with vascular...
-
Divergent transcriptomic signatures from putative mesenchymal stimuli in glioblastoma cells
In glioblastoma, a mesenchymal phenotype is associated with especially poor patient outcomes. Various glioblastoma microenvironmental factors and...
-
Polymeric Nanoparticles to Target Glioblastoma Tumors
Glioblastoma multiforme is a frequent tumor of the central nervous system in adults. Actual treatments allow a survival time of about 15 months,...
-
Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma
Glioblastoma is highly aggressive and remains difficult to treat despite being the most common malignant primary brain tumor in adults. Current...
-
Optimizing CAR-T Therapy for Glioblastoma
Chimeric antigen receptor T-cell therapies have transformed the management of hematologic malignancies but have not yet demonstrated consistent...
-
A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells
Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and...
-
KRAS is a molecular determinant of platinum responsiveness in glioblastoma
BackgroundKRAS is the undisputed champion of oncogenes, and despite its prominent role in oncogenesis as mutated gene, KRAS mutation appears...
-
Automated glioblastoma patient classification using hypoxia levels measured through magnetic resonance images
IntroductionThe challenge of treating Glioblastoma (GBM) tumors is due to various mechanisms that make the tumor resistant to radiation therapy. One...
-
New insights into targeted therapy of glioblastoma using smart nanoparticles
In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense...
-
The role of histone H3 lysine demethylases in glioblastoma
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with an average survival of 15–18 months. Part of its malignancy derives from...
-
MTAP loss: a possible therapeutic approach for glioblastoma
Glioblastoma is the most lethal form of brain tumor with a recurrence rate of almost 90% and a survival time of only 15 months post-diagnosis. It is...
-
Syngeneic Mouse Model of Glioblastoma: Intracranial Implantation of GL261 Cells
Glioblastoma (GBM) is the most aggressive and prevalent primary brain malignancy in adults. Current treatments provide limited benefit, and thus, the...
-
Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
BackgroundGlioblastoma (GBM) is the most malignant among gliomas with an inevitable lethal outcome. The elucidation of the physiology and regulation...
